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Abstract Autism is a neurodevelopmental disorder
of unclear etiology. The consistent finding of platelet
hyperserotonemia in a proportion of patients and its
heritability within affected families suggest that genes
involved in the serotonin system play a role in this
disorder. The role in autism etiology of seven can-
didate genes in the serotonin metabolic and neuro-
transmission pathways and mapping to autism linkage
regions (SLC6A4, HTR1A, HTR1D, HTR2A,
HTR5A, TPH1 and ITGB3) was analyzed in a sam-
ple of 186 nuclear families. The impact of interac-
tions among these genes in autism was assessed using
the multifactor-dimensionality reduction (MDR)
method in 186 patients and 181 controls. We further
evaluated whether the effect of specific gene variants
or gene interactions associated with autism etiology
might be mediated by their influence on serotonin
levels, using the quantitative transmission disequilib-
rium test (QTDT) and the restricted partition
method (RPM), in a sample of 109 autistic children.
We report a significant main effect of the HTR5A
gene in autism (P = 0.0088), and a significant three-
locus model comprising a synergistic interaction
between the ITGB3 and SLC6A4 genes with an
additive effect of HTR5A (P < 0.0010). In addition to
the previously reported contribution of SLC6A4, we
found significant associations of ITGB3 haplotypes
with serotonin level distribution (P = 0.0163). The
most significant models contributing to serotonin
distribution were found for interactions between
TPH1 rs4537731 and SLC6A4 haplotypes (P = 0.002)
and between HTR1D rs6300 and SLC6A4 haplotypes
(P = 0.013). In addition to the significant indepen-
dent effects, evidence for interaction between
SLC6A4 and ITGB3 markers was also found. The
overall results implicate SLC6A4 and ITGB3 gene
interactions in autism etiology and in serotonin level
determination, providing evidence for a common
underlying genetic mechanism and a molecular
explanation for the association of platelet hyperse-
rotonemia with autism.
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Introduction
Autism (AD; OMIM 209850) is a heritable complex
neurodevelopmental disorder characterized by
impairments in social interaction and communication,
and restricted and stereotyped patterns of interests and
behaviors (Lord et al. 2000). Although the etiology of
autism is not understood, several lines of evidence
indicate that the serotonin (5-HT) system may play an
important role. Serotonin is a monoamine neuro-
transmitter involved in the regulation of biological
functions such as emotional behavior, sleep, pain sen-
sitivity and hormone release, and plays a crucial role in
synaptogenesis and brain development. One of the few
consistent findings in autism is platelet hyperseroton-
emia in a proportion of patients. Platelet serotonin
levels have been shown to be highly heritable, both in
healthy and in autistic individuals (Abney et al. 2001;
Ober et al. 2001; Coutinho et al. 2004). It is therefore
plausible that the increased serotonin levels found in
autism are genetically determined, and thus the quan-
tification in platelets reflects the levels both in the
mature central nervous system (CNS) and during
development, at times when the brain may be partic-
ularly sensitive to abnormal neurotransmitter function.
Increased levels of 5-HT and/or anomalous transmis-
sion during the prenatal and early postnatal period are
hypothesized to result in abnormal synaptogenesis and
brain development, with consequent behavioral mani-
festations that could be variable according to the brain
area affected and to the timing of the insult, and which
would persist throughout life in autistic individuals
(Whitaker-Azmitia 2005). The genetic factors deter-
mining serotonin levels have not been fully established,
but are likely candidate genes for autism etiology that
can be identified as quantitative trait loci (QTLs) for
serotonin levels and confirmed as autism susceptibility
factors.
Multiple molecules involved in serotonin metabo-
lism and neurotransmission are known to or have the
capacity to regulate serotonin levels in the brain, and
are often targets for genetic and pharmacological
studies in autism. Some of these molecules are encoded
by genes mapping to autism linkage regions. For in-
stance, the serotonin transporter gene SLC6A4 and the
gene encoding the integrin b3 subunit ITGB3, which
were both identified as QTLs for serotonin levels
(Weiss et al. 2004, 2005a), are located on 17q11.1-q12
and 17q21.32, respectively, under two linkage peaks for
autism (Stone et al. 2004; Cantor et al. 2005). The
serotonin receptor genes HTR2A on 13q14-q21 and
HTR5A on 7q36.1, also map to regions identified by
linkage screens for autism (Barrett et al. 1999; Brad-
ford et al. 2001; Alarco´n et al. 2002; Auranen et al.
2002). The SLC6A4 gene has received particular
attention, chiefly because the serotonin transporter is a
target for selective serotonin reuptake inhibitor (SSRI)
drugs that are effective in neuropsychiatric disorders.
Various groups have reported the association of poly-
morphic markers within this gene with autism, includ-
ing an insertion/deletion polymorphism in the
promoter that regulates the serotonin reuptake rate
(Lesch et al. 1996); however, the associated alleles
were often not consistent among studies, and the re-
sults were not replicated in several other population
samples (Devlin et al. 2005). In a previous study, we
have shown that abnormally high platelet 5-HT levels
in autistic children are partly explained by genetic
variants in SLC6A4, although an association of this
gene with autism could not be established in our pop-
ulation sample (Coutinho et al. 2004). This suggests
that while SLC6A4 could act as a major gene, other
genes are very likely interacting with it in the deter-
mination of hyperserotonemia associated with autism.
The observations were consistent with reported dif-
ferences in narrow and broad heritability of 5-HT level
estimates which suggest that more than one gene is
influencing this trait in a nonadditive manner (Abney
et al. 2001; Ober et al. 2001), and with the recent
genome-wide scan results for whole blood 5-HT, which
identified two QTLs on 17q, SLC6A4 and ITGB3.
Several other genes encoding molecules involved in the
5-HT system are plausible candidates for a role in the
determination of serotonin levels. The 5-HT autore-
ceptors 5-HT1A and 5-HT1D play an inhibitory role in
5-HT neurotransmission, while a reduced number of
platelet 5-HT2A binding sites is present in autistic
children with high 5-HT levels and their parents
(McBride et al. 1989; Cook et al. 1993), suggesting the
involvement of specific variants of the genes encoding
these receptors in hyperserotonemia in autistic pa-
tients. The 5-HT5A receptor gene HTR5A is mainly
expressed in the CNS, also suggesting an important
role in mediating the central effects of 5-HT. Trypto-
phan hydroxylase 1 (TPH1), which catalyzes the rate-
limiting step in the synthesis of 5-HT, is located both in
the periphery and in the CNS (Zill et al. 2005), and
therefore alterations in the TPH1 gene may be in-
volved in any phenotype resulting from a dysfunction
of the 5-HT system.
The multiplicity of possible players in the regulation
of serotonin levels indicates that interactions between
genes, or epistasis, are important in the definition of
this phenotype. Epistasis is thought to occur to allow
genetic buffering, i.e., to stabilize a phenotype through
the requirement that several genes in a gene network
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are mutated before a substantial effect on the pheno-
type takes place. It is therefore likely that epistasis is a
ubiquitous component of the genetic architecture of
complex traits, in which the correlations between
genotype and phenotype are usually nonlinear not only
because of genetic heterogeneity but also due to gene–
environment and gene–gene interactions (Ritchie et al.
2001; Moore 2003b, 2005; Thornton-Wells et al. 2004).
It is conceivable if not likely that epistasis in the ab-
sence of detectable independent effects of any gene
may impact on a phenotype, thus significantly ham-
pering the power of current statistical genetics methods
to uncover the genetic basis of complex traits. A re-
search approach that takes into account gene interac-
tions may therefore be a more useful strategy for this
purpose.
In the present study, we analyzed the role in autism
etiology of seven candidate genes in the serotonin
metabolic and neurotransmission pathways and sear-
ched for the occurrence of epistatic effects among
them. For this purpose, we focused on genes with an
established biological role in the serotonin pathway
that were located near linkage peaks for autism or had
been reported to influence serotonin level distribution,
and selected mainly functional polymorphisms that
might regulate serotonin levels. We further evaluated
whether the impact of specific gene variants and gene
interactions in autism etiology might be mediated by
their influence on serotonin levels, thus seeking a
better understanding of the importance of serotonin
levels for the pathophysiology of this disorder and
eventually for autism treatment.
Materials and methods
Subjects and clinical assessments
One hundred and eighty six autistic patients and their
parents were recruited at the Hospital Pedia´trico de
Coimbra (HP), originating from mainland Portugal
(N = 171) and the Azorean islands (N = 15). The
male-to-female ratio was of 4.8:1, and the age ranged
from 2 to 18 years (mean 6.8 years). Patients were
diagnosed using DSM-IV criteria (American Psychi-
atric Association 1994), the Autism Diagnostic Inter-
view-Revised (ADI-R) (Lord et al. 1994) and the
Childhood Autism Rating Scale (CARS) (Schopler
et al. 1988). Idiopathic subjects were included after
clinical assessment and screening for known medical
and genetic associated conditions. Neuropsychological
evaluation was performed using the Ruth Griffiths
Mental Developmental Scale II (Griffiths 1984) or the
Wechsler Intelligence Scale for Children (WISC 1974).
Control adults consisted of 181 unrelated healthy blood
donors (male:female ratio of 3.9:1) with no family
history of neuropsychiatric diseases, recruited at the
Centro Regional de Sangue de Lisboa and at the
Hospital Egas Moniz. Control children consisted in 38
unrelated healthy individuals (male:female ratio of
1.3:1), recruited at the HP. The study was approved by
the HP ethical committee, and all participants or legal
representatives signed an informed consent.
Measurement of platelet serotonin levels
Platelet serotonin content was measured by high per-
formance liquid chromatography (HPLC) in 109
autistic patients and their parents, as previously de-
scribed (Coutinho et al. 2004). Serotonin levels were
analyzed in subjects free of medication. In a previous
study (Coutinho et al. 2004), we found no correlation
of platelet serotonin levels with sex or age, and
therefore these parameters were not used as covariates
in the present analysis.
Genotyping
A blood sample from the patients, their parents, and
control individuals was used for DNA extraction by
salting out (Lahiri and Nurnberger 1991). Genotyping
of polymorphisms in SLC6A4, HTR2A, HTR1D,
HTR2A, HTR5A, and TPH1 was based on previously
described methods (see Supplementary Table S1). Two
polymorphisms in the HTR1A gene (see Supplemen-
tary Table S1), were genotyped through the Amplifluor
System
TM
(KBiosciences, UK) or by PCR-RFLP
through insertion of a restriction site, as follows. The
PCR (30 cycles at 94C for 30 s, 57C for 30 s, and
72C for 30 s) was performed with 25 ng of genomic
DNA, 200 lM of each dNTP (Promega), 2 mM of
MgCl2 (Promega), 1 · PCR buffer (Promega), 1.5 U of
Taq polymerase, and 0.4 lM of each primer (final
volume of 12.5 ll). For rs6295 and rs878567, the
polymorphisms were detected by restriction with TaqI
(Roche) and ApeKI (New England Biolabs), respec-
tively, according to the manufacturer’s instructions,
and resolved by electrophoresis in a 2.5% conventional
agarose gel. Two polymorphisms in ITGB3 (see Sup-
plementary Table S1) were genotyped as follows. For
rs5918, the PCR (30 cycles at 94C for 30 s, 60C for
30 s, and 72C for 30 s) was performed with 37.5 ng of
genomic DNA, 200 lM of each dNTP (Promega),
2 mM of MgCl2 (Promega), 1 · PCR buffer (Promega),
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1.5 U of Taq polymerase, and 0.36 lM of each primer
(final volume of 12.5 ll). For rs15908, the PCR (30
cycles at 94C for 30 s, 57C for 30 s, and 72C for 30 s)
was performed with 37.5 ng of genomic DNA, 200 lM
of each dNTP (Promega), 2 mM of MgCl2 (Promega),
1 · PCR buffer (Promega), 1.5 U of Taq polymerase,
and 1.2 lM of each primer (final volume of 12.5 ll).
For rs5918 and rs15908, the polymorphisms were de-
tected by restriction with HpaII (Fermentas) and TaqI
(Roche) respectively, according to the manufacturer’s
instructions, and resolved by electrophoresis in a 2%
conventional agarose gel.
Statistical analysis
The effects of each marker in association with autism
etiology were assessed using the Extended Transmis-
sion Disequilibrium Test (ETDT, version 2.4) for
individual markers (Sham and Curtis 1995) and
TRANSMIT (Clayton 1999), version 2.5.2, for hapl-
otypes. Testing for genetic interactions in association
with autism was performed using the multifactor-
dimensionality reduction (MDR) method (Ritchie
et al. 2001; Moore 2004), version beta 1.0.0 RC1,
available from http://www.epistasis.org/mdr.html. The
details of the MDR method have been presented
elsewhere (Ritchie et al. 2001; Moore 2004; Moore
et al. 2006). Briefly, a set of n polymorphisms are
selected. The n polymorphisms and their possible
multilocus classes are represented in n-dimensional
space; for example, for two loci with three genotypes
each, there are nine possible two-locus genotype
combinations. Then, the ratio for the number of cases
to the number of controls is calculated within each
multilocus class. Each multilocus class in n-dimen-
sional space is then labeled as ‘‘high-risk’’ if the cases
to controls ratio meets or exceeds some threshold
(e.g., ‡1), or as ‘‘low-risk’’ if that threshold is not
exceeded; the method thus reduces the n-dimensional
space to one dimension with two levels (‘‘low-risk’’
and ‘‘high-risk’’). The process of creating a new var-
iable as a function of two or more variables is called
constructive induction (Moore et al. 2006). This new
single MDR variable is assessed for its ability to
classify subjects as sick or healthy using a naı¨ve Bayes
classifier. All possible combinations of polymorphisms
are evaluated and the best selected as the model that
is most likely to generalize to independent datasets as
assessed by estimating a testing balanced accuracy
(TBA) with ten-fold cross-validation. Balanced accu-
racy is defined as the arithmetic mean of sensitivity
and specificity:
1/ 2 (TP=TP þ FN þ TN=TN þ TPÞ
¼ ðsensitivity þ specificityÞ=2
where TP are true positives, TN are true negatives, and
FN are false negatives (Velez et al. 2006). Cross vali-
dation divides the data into a training set and a testing
set in order to assess generalizability (Coffey et al.
2004). With ten-fold cross validation, the data are di-
vided into ten equal parts, and the model is developed
on 9/10 of the data (training set) and then tested on 1/
10 of the remaining data (testing set). This is repeated
for each possible 9/10 and 1/10 of the data, and the
resulting ten testing accuracies averaged (Hastie et al.
2001). In addition to the testing accuracy, we also re-
port the cross validation consistency (CVC) that is a
measure of how many times out of ten divisions of the
data that MDR found the same best model (Moore
2003a). Models that are true positives are likely to
generalize to independent datasets and will have esti-
mated testing accuracies of greater than 0.5. Permu-
tation testing was performed to assess the probability
of obtaining a testing accuracy as large or larger than
observed in the original data given the null hypothesis
of no association is true. This is carried out by ran-
domizing the case-control labels 1,000 times and
repeating the MDR analysis on each randomized
dataset. This process yields an empirical distribution of
testing balanced accuracies under the null hypothesis
that is in turn used to calculate a P value. Permutation
testing is important to correct for multiple testing
(Good 2000). MDR was run for models with two and
three marker combinations between the individual
markers or haplotypes. Missing genotypes were im-
puted with MDR data tool software (beta version
0.4.3), which allows the global replacement of un-
known values and the imputation of the data from a
model constructed by the software from the existing
dataset. Unknown haplotypes were estimated with the
program PHASE (Stephens et al. 2001), version 2.1.1.
The population sample used for the MDR test con-
sisted of 186 autistic children and 181 healthy adult
controls. Using approximately the same number of
cases and controls allows for an increase in power; for
this analysis, the ratio cases/controls was 1.03. Geno-
typic combinations for which the ratio cases/controls
was equal to 1.03 were set to be classified as unknown
risk. The models presenting the maximum TBA were
selected as the best MDR models.
To confirm, visualize, and interpret the genetic
interactions identified, MDR allows the construction of
interaction dendograms (Moore et al. 2006). This
graph plots the interactions between the variables
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tested (determined by interaction entropy analysis) in
hierarchical clustering, placing the most strongly
interacting variables close together at the leaves of the
tree. Interaction entropy is a measure of information
gain (i.e., percentage of entropy removed) on case-
control status from merging two variables together
over that provided by the two variables independently.
Additive and nonadditive interactions, as well as
redundancy, can thus be easily visualized and used to
interpret the MDR models.
Statistical analysis of platelet 5-HT levels was per-
formed following logarithmic (ln) transformation of
the quantitative variable, in order to approach a nor-
mal distribution. Analysis with haplotypes was per-
formed only when it was possible to establish phase. To
test the main effect of each marker on the 5-HT dis-
tribution, quantitative transmission disequilibrium
tests (QTDT) were performed, implemented in the
QTDT software, version 2.4.6 (Abecasis et al. 2000).
The orthogonal model of association was considered,
including variance components (individual and nuclear
family environment and a polygenic component). This
test, based on maximum-likelihood estimates, allows
variance components testing of family-based samples
for association and transmission disequilibrium, esti-
mating the relative weight of each contributor to the
phenotype. Association is partitioned into between-
and within-family components, the test for the latter
being free of confounding population substructure ef-
fects, regardless of the nuclear family composition. The
broad heritability of platelet serotonin levels was
determined using QTDT, by testing the significance of
the polygenic variance component of the trait distri-
bution; a null model including solely an environmental
component of variance was compared to a full model
including this and a polygenic variance component.
Genetic interactions in the determination of platelet 5-
HT levels were tested using the restricted partition
method (RPM) (Culverhouse et al. 2004), in a sample
of 109 autistic children and 38 age-matched controls.
RPM is a model-free method for detecting and char-
acterizing nonadditive interactions among discrete ge-
netic and environmental factors that contribute to
quantitative trait variation. The goal of RPM is to find
partitions of multilocus genotypes that explain a sig-
nificant proportion of the observed trait variation. For
each model, a coefficient of determination (R2) is
estimated for the quantitative trait value regressed on
the final genotype groups, and is a measure of the
proportion of the total variance explained by the
groups of the respective model. We ran RPM for two-
way interactions between the 11 individual markers
and haplotypes, in a total of 97 tests performed. The
significance of each model was validated with 9,700
permutations, according to the number of tests (num-
ber of permutations = [1/(0.05/number of tests)] · 5),
in order to generate a large enough empirical null
distribution to yield a P value with the desired preci-
sion (a = 0.05). In the permutation test, the data trait
values are randomized and, for each permutated data,
RPM is performed and the R2 is estimated. The sig-
nificance of each model is assessed by the frequency
with which the R2 from the original data exceeds the
permutated R2 values. Only groups with more than one
individual were considered in the analysis. Due to the
small sample size, no more than two-way interactions
were tested.
Results
To assess individual contributions of each marker in
autism etiology, the TDT was carried out for 11 indi-
vidual markers in the seven candidate genes and their
respective haplotypes (Tables 1, 2). A significant main
effect in autism was found for HTR5A rs1800883
marker (P = 0.0088), with allele –19G significantly
overtransmitted to the autistic probands (Table 1). A
specific haplotype of HTR5A markers containing the
undertransmitted –19C allele was significantly less
transmitted than expected (P = 0.0333) (Table 2). No
significant associations were found with other individ-
ual markers or haplotypes.
The MDR method was used to assess the impact of
two- and three-way combinations between the 11
individual markers in autism etiology (Table 3). The
best two-marker model selected by MDR was an
interaction between SLC6A4 intron 2 VNTR and
ITGB3 rs5918, with a maximum testing balanced
accuracy (TBA) of 0.6357, thus being able to classify
correctly 64% of the individuals used in the analysis
(P < 0.001), and with a cross-validation consistency
(CVC) of 6/10. The best three-marker model identified
included these two markers and added HTR5A rs6320,
increasing the TBA to 67% (P < 0.001), and with a
CVC of 4/10. A two-way model between SLC6A4 and
ITGB3 marker haplotypes was also significant, with a
TBA of 0.5853 (P = 0.020), but with a CVC of 9/10.
The best three-way marker haplotype model again in-
cluded markers in SLC6A4, ITGB3, and HTR5A
(TBA = 0.6066, P = 0.009 and CVC of 10/10). This
indicates that interaction between genetic variants at
SLC6A4 and ITGB3 genes is associated with increased
risk for autism, a finding compatible with the linkage
peaks for autism on chromosome 17q, in the regions
where these genes map (Stone et al. 2004; Cantor et al.
Hum Genet (2007) 121:243–256 247
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2005). Three-way genetic combinations between these
two genes and HTR5A are also associated with in-
creased risk for autism, in agreement with the main
effect in autism found for HTR5A in this sample (see
Supplementary Table S2 for a detailed description of
the genotypic combinations associated with high- and
low-risk for autism for the MDR best models).
The interaction dendograms shown in Fig. 1a, b al-
low a better interpretation of the genetic effects iden-
tified by MDR. As expected, the strongest synergy
among individual markers (Fig. 1a, line 1) was found
between SLC6A4 intron 2 VNTR and ITGB3 rs5918,
indicative of a nonadditive effect. Synergy was mod-
erate for markers HTR1A rs6295 and HTR5A rs6320
(Fig. 1a, line 2); however, this model was not good in
predicting disease-risk status for autism (CVC of 0/10),
and was not selected by the MDR analysis. Impor-
tantly, the Fig. 1a interaction dendogram shows that
for the best three-marker model associated with aut-
ism, SLC6A4 intron 2 VNTR and ITGB3 rs5918 act
synergistically but HTR5A rs6320 contributes with an
additive effect to the model (Fig. 1a, line 3). This
interpretation is consistent with the individual associ-
ation of HTR5A with autism. Figure 1b corroborates
these results, displaying a strong synergy between
SLC6A4 and ITGB3 marker haplotypes (line 1) but an
additive effect of HTR5A haplotypes (line 3).
Our sample provides a very significant evidence of a
polygenic component (P = 5 · 10–7) for platelet sero-
tonin levels, for which the broad heritability was esti-
mated at 64%. The individual contributions of
candidate gene marker alleles and haplotypes to
platelet serotonin levels in autistic children were as-
sessed using QTDT. In addition to the previously re-
Table 1 Transmission
disequilibrium test results
(ETDT analysis), to assess the
main effects of each marker in
association with autism
etiology
T transmitted, NT not
transmitted
Marker Allele T NT v2 (df) P value
TPH1 rs4537731 –6526G 85 82 0.054 (1) 0.8164
–6526A 82 85 0.054 (1) 0.8164
Global test 0.054 (1) 0.8164
HTR2A rs6311/rs6313 –1438A/102T 72 71 0.007 (1) 0.9334
–1438G/102C 71 72 0.007 (1) 0.9334
Global test 0.007 (1) 0.9333
HTR1D rs6300 1080T 33 26 0.831 (1) 0.3622
1080C 26 33 0.831 (1) 0.3622
Global test 0.832 (1) 0.3616
SLC6A4 5-HTTLPR L 71 71 0.000 (1) 1.0000
S 71 71 0.000 (1) 1.0000
Global test 0.000 (1) 1.0000
SLC6A4 intron 2 VNTR Stin2.9 2 1 not tested
Stin2.10 70 52 2.656 (1) 0.1032
Stin2.12 53 72 2.888 (1) 0.0893
Global test 3.005 (2) 0.2226
ITGB3 rs5918 Leu33 43 35 0.821 (1) 0.3651
Pro33 35 43 0.821 (1) 0.3651
Global test 0.822 (1) 0.3647
ITGB3 rs15908 1143A 67 76 0.566 (1) 0.4517
1143C 76 67 0.566 (1) 0.4517
Global test 0.567 (1) 0.4516
HTR1A rs6295 –1019C 88 82 0.212 (1) 0.6454
–1019G 82 88 0.212 (1) 0.6454
Global test 0.212 (1) 0.6454
HTR1A rs878567 1556T 81 90 0.474 (1) 0.4913
1556C 90 81 0.474 (1) 0.4913
Global test 0.474 (1) 0.4912
HTR5A rs1800883 –19G 81 51 6.818 (1) 0.0091
–19C 51 81 6.818 (1) 0.0091
Global test 6.878 (1) 0.0088
HTR5A rs6320 12A 74 69 0.175 (1) 0.6759
12T 69 74 0.175 (1) 0.6759
Global test 0.175 (1) 0.6758
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ported contribution of SLC6A4 haplotypes (Coutinho
et al. 2004), we found significant associations of ITGB3
rs5918 marker and rs5918/rs15908 haplotypes with
serotonin level distribution (Table 4). The rs5918
marker allele Pro33 was positively associated with
5-HT levels in autistic children (P = 0.0055), account-
ing for 16.9% of the phenotypic variance, replicating
previous findings of an association of this allele with
5-HT levels towards the high end of the distribution in
a healthy population (Weiss et al. 2004, 2005a, 2005b).
A significant global association was also observed for
ITGB3 rs5918/rs15908 haplotypes (P = 0.0163), with
haplotype Pro33/1143C showing a significant positive
association with the trait (P = 0.0019). The proportion
of variance accounted for by this haplotype, estimated
at 24.5%, was increased in relation to the indepen-
dently associated rs5918 marker. Altogether, these re-
sults demonstrate significant main individual effects of
SLC6A4 and ITGB3 in the determination of platelet
5-HT levels, which account for a significant proportion
of the genetic trait variation in an autistic population.
No associations were found with the remaining mark-
ers tested.
Interaction effects among the candidate gene
markers contributing to the determination of 5-HT
levels were modeled using RPM. Interactions were
tested for all possible two-way marker and haplotype
combinations, and are shown in Table 5 (see Supple-
mentary Table S3 for detailed information about
the genotypic combinations of the significant RPM
Table 2 Transmission disequilibrium test results (TRANSMIT analysis), to assess the main effects of each marker haplotype in
association with autism etiology
Marker Haplotype Observed Expected v2 (df) P value
SLC6A4 5-HTTLPR/intron 2 VNTR L/Stin2.9 3.144 1.654 2.961 (1) 0.0853
S/Stin2.9 0.045 0.563 1.074 (1) 0.3000
L/Stin2.10 98.052 88.320 3.304 (1) 0.0691
S/Stin2.10 35.701 34.560 0.107 (1) 0.7440
L/Stin2.12 82.287 90.952 2.568 (1) 0.1090
S/Stin2.12 120.770 123.950 0.295 (1) 0.5868
Global test 8.502 (5) 0.1306
ITGB3 rs5918/rs15908 Leu33/1143A 169.860 171.110 0.045 (1) 0.8325
Pro33/1143A 5.142 5.945 0.234 (1) 0.6285
Leu33/1143C 87.142 80.438 1.546 (1) 0.2137
Pro33/1143C 35.858 40.510 1.259 (1) 0.2618
Global test 2.332 (3) 0.5065
HTR1A rs6295/rs878567 –1019C/1556T 3.508 6.119 2.478 (1) 0.1155
–1019G/1556T 160.760 162.570 0.075 (1) 0.7842
–1019C/1556C 185.160 180.540 0.494 (1) 0.4821
–1019G/1556C 10.570 10.767 0.011 (1) 0.9159
Global test 3.751 (3) 0.2897
HTR5A rs1800883/rs6320 –19G/12A 104.150 102.110 0.120 (1) 0.7286
–19C/12A 4.501 4.186 0.056 (1) 0.8127
–19G/12T 142.900 132.490 2.551 (1) 0.1102
–19C/12T 94.446 107.210 4.532 (1) 0.0333
Global test 4.825 (3) 0.1851
Table 3 Best models assessed by the MDR method for two-way and three-way combinations, to test for epistasis in association with
autism etiology
Nb.
markers
Best models Cross-validation
consistency
Testing balanced
accuracy (Empirical
P value)
Odds-ratio
(95% Confidence
Interval)Marker 1 Marker 2 Marker 3
2 SLC6A4 intron
2 VNTR
ITGB3 rs5918 6/10 0.6357 (<0.001) 3.24 (2.12–4.97)
2 TPH1 rs4537731 HTR5A rs6320 4/10 0.6348 (<0.001) 3.36 (2.18–5.17)
3 SLC6A4 intron
2 VNTR
ITGB3 rs5918 HTR5A rs6320 4/10 0.6676 (<0.001) 4.84 (3.11–7.54)
3 HTR2A
rs6311/rs6313
SLC6A4 intron
2 VNTR
HTR5A rs6320 4/10 0.6462 (<0.001) 4.68 (3.01–7.27)
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models). The analysis was restricted to two-way com-
binations because, given the present sample size, when
testing higher-order interactions we would expect
many two-locus genotypes to be void or have very few
observations. The most significant models contributing
to 5-HT distribution were found for interactions be-
tween TPH1 rs4537731 and SLC6A4 haplotypes
(P = 0.002) and between HTR1D rs6300 and SLC6A4
haplotypes (P = 0.013). Most interestingly, interactions
between SLC6A4 haplotypes and the ITGB3 markers
rs5918 (P = 0.037) and rs15908 (P = 0.035) also sig-
nificantly contribute to trait distribution. Interaction
between marker haplotypes in both genes was not
significant, likely because the number of individuals
used in the analysis of this particular model was lower
(N = 97), with a consequent loss of statistical power.
Other significant interactions were found in association
with 5-HT levels, namely ITGB3 rs5918 with HTR5A
rs6320 (P = 0.027), and ITGB3 haplotypes with
HTR1A haplotypes (P = 0.030).
Because we initially hypothesized that a common set
of genes or gene interactions might bear an impact in
autism by contributing to the determination of 5-HT
levels, we tested whether the interaction models iden-
tified as contributing the most to serotonin distribution
using RPM might also be associated with autism. For
this purpose, we analyzed the TBA and CVC of
interaction models tested by MDR but not selected as
best models. We found that two of the interaction
models most significantly contributing to 5-HT distri-
bution were also associated with autism, namely the
interaction of TPH1 rs4537731 with SLC6A4 haplo-
types (TBA = 0.5941, P = 0.015) and the interaction of
ITGB3 rs5918 with HTR5A rs6320 (TBA = 0.5923,
P = 0.025); however for both these models the CVC
was 0/10, and analysis of the corresponding interaction
dendograms indicates that there is redundancy and
additivity, respectively, between the marker variants.
The other interaction models significantly contributing
to 5-HT determination were not significantly associ-
ated with autism, except for those that included
SLC6A4 and ITGB3 markers, as already referred.
The overall results therefore consistently implicate
the SLC6A4 and ITGB3 genes in autism etiology and
in serotonin level determination and show that inter-
action between the same genetic variants is associated
with both traits, strongly suggesting a causal relation-
ship.
Discussion
The main purpose of the present paper was to further
our understanding of the role of serotonin pathway
genes in autism. We report a significant main effect of
the HTR5A gene in autism, with a significant associa-
Fig. 1 Interaction
dendograms for the markers
tested in the MDR analysis
for association with autism. a
Interactions between the 11
individual markers, clearly
showing a strong synergistic
effect (epistasis) between
SLC6A4 intron 2 VNTR and
ITGB3 rs5918 (line 1); weaker
synergy is found between
HTR1A rs6295 and HTR5A
rs6320 (line 2); redundancy is
found for TPH1 rs4537731
and HTR1A rs878567
markers (line 4); additivity
lines (line 3) confirm the
independent effect of the
HTR5A rs6320 marker over
SLC6A4 intron 2 VNTR and
ITGB3 rs5918. b Interactions
between haplotypes, where
the strong synergy between
SLC6A4 and ITGB3 and the
additive effect of HTR5A
with these two genes are
confirmed; redundancy
between markers is shown by
lines 4 and 5
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Table 4 QTDT orthogonal tests of association with variance components, to assess the main effects of each marker and respective
haplotypes in association with platelet serotonin levels
Marker Allele v2 (df) P value Direction of
association
Proportion of phenotypic
variance accounted by
each allele/haplotype (%)
ITGB3 rs5918 Leu33 7.71 (1) 0.0055 Negative 16.9
Pro33 7.71 (1) 0.0055 Positive 16.9
Global test 7.71 (1) 0.0055
ITGB3 rs15908 1143A 1.57 (1) >0.1
1143C 1.57 (1) >0.1
Global test 1.57 (1) 0.2108
ITGB3 rs5918/rs15908 Leu33/1143A 2.31 (1) >0.1
Leu33/1143C 0.37 (1) >0.1
Pro33/1143A Not tested Not tested
Pro33/1143C 9.68 (1) 0.0019 Positive 24.5
Global test 10.29 (3) 0.0163
SLC6A4 5-HTTLPR L 5.72 (1) 0.0168 Positive 11.2
S 5.72 (1) 0.0168 Negative 11.2
Global test 5.72 (1) 0.0168
SLC6A4 intron 2 VNTR Stin2.10 3.92 (1) 0.0477 Positive 8.3
Stin2.12 3.91 (1) 0.0480 Negative 8.5
Global test 3.95 (1) 0.0468
SLC6A4 5-HTTLPR/intron 2 VNTR L/Stin2.10 10.34 (1) 0.0013 Positive 18.4
L/Stin2.12 0.00 (1) >0.1
S/Stin2.10 1.16 (1) >0.1
S/Stin2.12 4.10 (1) 0.0429 Negative 9.1
Global test 12.08 (3) 0.0168
TPH1 rs4537731 –6526G 0.43 (1) >0.1
–6526A 0.43 (1) >0.1
Global test 0.43 (1) 0.5128
HTR1A rs6295 –1019C 0.66 (1) >0.1
–1019G 0.66 (1) >0.1
Global test 0.66 (1) 0.4150
HTR1A rs878567 1556T 0.09 (1) >0.1
1556C 0.09 (1) >0.1
Global test 0.09 (1) 0.7687
HTR1A rs6295/rs878567 –1019C/1556T Not tested Not tested
–1019C/1556C 0.11 (1) >0.1
–1019G/1556T 0.28 (1) >0.1
–1019G/1556C Not tested Not tested
Global test 0.68 (3) 0.7135
HTR1D rs6300 1080T 0.28 (1) >0.1
1080C 0.28 (1) >0.1
Global test 0.28 (1) 0.5941
HTR2A rs6311/rs6313 –1438A/102T 1.31 (1) >0.1
–1438G/102C 1.31 (1) >0.1
Global test 1.31 (1) 0.2523
HTR5A rs1800883 –19G 0.63 (1) >0.1
–19C 0.63 (1) >0.1
Global test 0.63 (1) 0.4279
HTR5A rs6320 12A 0.47 (1) >0.1
12T 0.47 (1) >0.1
Global test 0.47 (1) 0.4926
HTR5A rs1800883/rs6320 –19G/12A 0.09 (1) >0.1
–19G/12T 0.01 (1) >0.1
–19C/12A Not tested >0.1
–19C/12T 0.00 (1) >0.1
Global test 1.20 (3) 0.7531
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tion of a specific marker and one significantly under-
transmitted haplotype. This gene maps to a linkage
region previously identified for autism, which has been
suggested to contain a locus associated with restrictive–
repetitive behaviors (Alarco´n et al. 2002; Auranen
et al. 2002). The 5-HT5A receptor is mainly expressed
in the CNS (Rees et al. 1994) but not much is known
regarding its specific function. HTR5A knockout mice
show increased locomotor and exploratory behavior in
novel environments but no change in anxiety-related
behaviors (Grailhe et al. 1999). Activation of this
receptor in phase-shift studies also suggests a role in
circadian rhythm (Sprouse et al. 2004), which is
impaired in autistic patients with sleep problems
(Richdale and Prior 1995). While intriguing, this result
should be interpreted with caution. We did not correct
for multiple testing, as for small sample sizes common
procedures such as the Bonferroni correction, while
reducing the frequency of Type I errors, greatly in-
crease the probability of Type II errors, considerably
increasing the likelihood of missing out on genes of
small effect (Feise 2002). We therefore favor replica-
tion in a larger independent dataset to properly assess
the relevance of this finding.
We further identified a significant two-way interac-
tion between markers in SLC6A4 and ITGB3, indi-
cating that epistasis between variants in these two
genes is associated with increased risk to autism, even
though the same markers do not show an individual
association with the disease. This result may illustrate
an extreme case that could, however, be common for
complex traits, in which testing for interaction between
genes uncovers a genetic liability dependent on gene
interaction even when the genes involved show no
independent main effect on the phenotype. The most
significant model associated with autism was a three-
Table 5 RPM results for two-way interactions, to test for epistasis in the determination of platelet serotonin levels
Two-way model N Nb. groups R2 Empirical
P value
Marker 1 Marker 2
TPH1 rs4537731 SLC6A4 5-HTTLPR/intron 2 VNTR 122 3 0.251 0.002
HTR1D rs6300 SLC6A4 5-HTTLPR/intron 2 VNTR 122 2 0.161 0.013
SLC6A4 5-HTTLPR SLC6A4 intron 2 VNTR 138 2 0.099 0.018
TPH1 rs4537731 SLC6A4 5-HTTLPR 140 2 0.097 0.019
ITGB3 rs5918 HTR5A rs6320 140 2 0.070 0.027
HTR1A rs6295/rs878567 ITGB3 rs5918/rs15908 95 2 0.193 0.030
ITGB3 rs15908 SLC6A4 5-HTTLPR/intron 2 VNTR 115 2 0.209 0.035
HTR1D rs6300 SLC6A4 5-HTTLPR 139 2 0.065 0.036
ITGB3 rs5918 SLC6A4 5-HTTLPR/intron 2 VNTR 122 2 0.150 0.037
SLC6A4 5-HTTLPR HTR5A rs1800883 142 2 0.076 0.042
ITGB3 rs15908 HTR1A rs6295/rs878567 106 2 0.130 0.042
HTR1A rs878567 SLC6A4 5-HTTLPR/intron 2 VNTR 121 2 0.191 0.054
SLC6A4 5-HTTLPR HTR5A rs6320 141 2 0.069 0.057
HTR1A rs6295 SLC6A4 5-HTTLPR/intron 2 VNTR 122 2 0.197 0.064
HTR1A rs6295 ITGB3 rs5918 138 2 0.026 0.070
HTR2A rs6311/rs6313 SLC6A4 5-HTTLPR 140 2 0.077 0.071
SLC6A4 5-HTTLPR ITGB3 rs5918 140 2 0.060 0.071
HTR2A rs6311/rs6313 HTR5A rs1800883/rs6320 120 2 0.128 0.077
HTR1A rs6295 ITGB3 rs15908 135 2 0.072 0.078
HTR5A rs1800883 SLC6A4 5-HTTLPR/intron 2 VNTR 120 2 0.151 0.078
HTR1A rs6295 ITGB3 rs5918/rs15908 127 2 0.114 0.085
SLC6A4 5-HTTLPR HTR5A rs1800883/rs6320 123 2 0.124 0.104
SLC6A4 5-HTTLPR ITGB3 rs15908 135 2 0.066 0.110
SLC6A4 5-HTTLPR/intron 2 VNTR HTR1A rs6295/rs878567 90 2 0.223 0.120
SLC6A4 5-HTTLPR/intron 2 VNTR ITGB3 rs5918/rs15908 97 2 0.216 0.125
SLC6A4 5-HTTLPR HTR1A rs6295 139 2 0.060 0.130
HTR5A rs6320 SLC6A4 5-HTTLPR/intron 2 VNTR 123 2 0.127 0.130
SLC6A4 5-HTTLPR/intron 2 VNTR HTR5A rs1800883/rs6320 86 2 0.180 0.130
SLC6A4 5-HTTLPR HTR1A rs878567 139 2 0.060 0.150
HTR5A rs1800883 ITGB3 rs5918/rs15908 129 2 0.078 0.150
ITGB3 rs15908 HTR5A rs1800883 139 2 0.054 0.160
HTR2A rs6311/rs6313 SLC6A4 5-HTTLPR/intron 2 VNTR 125 2 0.176 0.160
HTR1A rs878567 ITGB3 rs15908 136 2 0.062 0.170
ITGB3 rs5918/rs15908 HTR5A rs1800883/rs6320 101 2 0.077 0.340
Only results with R2 above 0 and P value lower than 1.0 are shown
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way combination between SLC6A4, ITGB3, and
HTR5A, with an increased testing balanced accuracy
and correctly classifying 67% of the individuals tested.
Interpretation of this model using an interaction
dendogram shows a strong synergistic effect between
SLC6A4 and ITGB3 markers, but an additive effect of
HTR5A, consistent with the independent main effect
found for HTR5A in association with autism.
Significant independent effects in the regulation of
5-HT levels were observed for markers at SLC6A4 and
ITGB3, as expected given our previous observation of
an association of SLC6A4 variants with serotonin dis-
tribution in this sample, and reports of these two genes
as QTLs on chromosome 17q for whole blood seroto-
nin (Weiss et al. 2004, 2005a, 2005b). Importantly, an
overlapping linkage peak on 17q has been reported for
autism (Stone et al. 2004; Cantor et al. 2005; Sutcliffe
et al. 2005), pointing to the SLC6A4 and ITGB3 genes
as prime candidates for autism etiology. Previous
studies have reported the association of various poly-
morphisms in SLC6A4 with autism, which we do not
replicate in our population. A possible explanation is
that our sample size is inadequate for detection of this
effect, and/or that the tested loci are not causative but
in somewhat weak linkage disequilibrium (LD) with
the true causative mutation. However, as discussed in
Coutinho et al. (2004), we favor an explanation for this
discrepancy residing on the frequency of hypersero-
tonemia in different samples. Only 11.4% of our pa-
tients have hyperserotonemia. We therefore propose
that while genetic variants associated with platelet
hyperserotonemia are also contributing to autism sus-
ceptibility, these are not as frequent in our population.
In this context, it would be interesting to find out
whether hyperserotonemia is more frequent in samples
in which the SLC6A4 gene has been found associated
with autism. The present study provides further evi-
dence for a common genetic architecture underlying
autism and regulation of serotonin levels by showing
that the epistatic interaction of genetic variants of
these two genes contributes to the determination of
5-HT levels and is associated with autism. Two very
recent studies, in which association of ITGB3 with
autism and whole blood serotonin levels was reported
(Weiss et al. 2006a) and it was suggested that ITGB3
may interact with SLC6A4 in mediating autism sus-
ceptibility (Weiss et al. 2006b) lend further support to
our hypothesis. Notably, these were the single nonad-
ditive gene interactions consistent for autism and
serotonin distribution. Interpretation of the joint
results for the autism and 5-HT phenotypes indicates
that the HTR5A gene, independently or in combina-
tion with SLC6A4 and ITGB3, is not a major factor in
the regulation of serotonin levels and thus likely does
not contribute to autism etiology through the same
mechanism at the biological level. Other gene–gene
interactions were significant for the determination of
platelet serotonin distribution in our sample. For in-
stance, the results suggest that the increased 5-HT re-
uptake associated with specific functional variants of
the SLC6A4 gene (Meltzer and Arora 1988; Lesch
et al. 1996; Greenberg et al. 1999) could be reinforced
by increases in the synthesis of 5-HT mediated by se-
quence alterations in the TPH1 promoter (Sun et al.
2005). Evidence of a contribution to 5-HT level dis-
tribution was found for interactions involving SLC6A4
and HTR1D or HTR5A, and also ITGB3 and HTR1A
or HTR5A. An involvement of these molecules was
expected, given the roles of the encoded molecules in
serotonin transmission or metabolism, but we found no
evidence for a meaningful impact on the autistic phe-
notype.
The significant main effect and significant genetic
interactions between candidate genes here reported
cannot explain the entirety of trait variation. This is not
surprising, as the serotonin system pathway includes a
large number of components, and genetic interactions
not detected in our sample, as well as gene–environ-
ment effects that were not accounted in the analysis,
are likely contributors to these complex phenotypes.
The power of our analysis to detect genetic effects with
a minor contribution, however, was limited by the
small sample size and thus replication in a larger
independent sample is important.
By showing a common genetic architecture under-
lying the two traits, the results strongly suggest that, at
least for a proportion of autistic subjects, a genetically
determined increase in serotonin levels, with likely
important consequences for brain development and
function, contributes to autism etiology. We find
independent and interaction effects of the SLC6A4
and ITGB3 genes to contribute to the full range of
serotonin concentrations. Since only about 11.4% of
our patients have hyperserotonemia, the majority of
individuals tested fall in the normal portion of the
5-HT distribution, indicating that they have genotypes
at either gene and/or gene combinations that will
determine normal platelet serotonin levels. Only the
minority of hyperserotonemic patients are likely to
have the fatal combination of variants in the SLC6A4
and ITGB3 genes that will significantly contribute to a
dysfunction in serotonin regulation, which is reflected
in the increased platelet serotonin levels and may lead
to autism. We suggest that while each gene indepen-
dently strongly contributes to the 5-HT trait variation
in the normal range, the interaction of specific delete-
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rious variants of both genes will potentiate serotonin
dysregulation, reflected in increased serotonin levels in
the periphery and leading to brain dysfunction/disease.
We cannot rule out that each gene does not indepen-
dently contribute to autism in individuals with hyper-
serotonemia, but do find that the interaction has a
stronger effect on the phenotype that can be detected
even in a small sample of individuals in which hyper-
serotonemia is observed.
The biological mechanism, however, has yet to be
determined. A role for the serotonin transporter is
biologically sound, as this molecule is chiefly respon-
sible for the removal of serotonin from the synapses.
However, the association of specific transporter gene
variants with autism has not been consistent among
studies, even though it is clearly associated with sero-
tonin level variation. Janusonis (2005) has established a
theoretical model for serotonin release from gut
enterochromaffin (EC) cells to the blood stream pro-
posing that 5-HT levels are strongly dependent on a
serotonin monitoring factor in the extracellular space
that adjusts 5-HT release accordingly, while taking into
account the impact of mechanisms for 5-HT clearance,
namely the reuptake by the serotonin transporter and
the degradation by metabolic enzymes. The model
proposes that autistic individuals will have a molecular
defect that impairs the feedback mechanism regulating
serotonin release according to 5-HT levels, with the
transporter and other molecules involved in serotonin
clearance acting as modifiers. The evidence gathered in
the present study indicates that the b3 integrin subunit
may be involved in the regulation of serotonin release.
It is known that aIIbb3 integrin plays a key role in the
regulation of platelet aggregation and serotonin
secretion, through an outside–in signaling mechanism
that is regulated by the Leu33Pro ITGB3 polymor-
phism (Sajid et al. 2002; Vijayan et al. 2005). While the
existence of the b3 integrin subunit in the EC cells
model has not been documented, and thus no simple
projection/extrapolation can be made, the role of
ITGB3 in platelets and its expression in the brain,
where b3 integrins mediate functional pre and post-
synaptic maturation of synapses, as well as evidence
that blocking integrin activity after spinal cord injury
improves serotonergic innervation (Oatway et al.
2005), support this hypothesis.
In summary, we present evidence for a common
genetic mechanism underlying autism and serotonin
level distribution, thus providing a molecular expla-
nation for the association of platelet hyperserotonemia
with autism and suggesting a plausible pathological
mechanism. It is worth remarking that the alterations
in platelet 5-HT levels do not necessarily imply
changes in brain serotonin levels, but do reflect the
dysfunction of brain expressed genes with conse-
quences in brain development and function that may
lead to autism symptomatology. Functional studies are
now required to assess the biological meaning of the
statistical interactions identified in this work, but the
findings are compatible with biological observations
and theoretical models, and thus provide a solid basis
for functional work. Autism is a highly complex dis-
order, and testing for gene epistasis in association with
specific disease associated phenotypes is shown to be a
powerful strategy towards the identification of autism
pathophysiology.
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